🧪 Registered trialInsufficientexpanded accessOpen access

Provide Pre-approval Expanded Access of LY3437943

Eli Lilly and Company

ClinicalTrials.gov · June 5, 2026

Plain-language summary

Registered expanded_access trial (available). Provide pre-approval single patient expanded access of retatrutide for patients.

Ask the literature about retatrutide →

#retatrutide

Trial record

Registered clinical trial record on ClinicalTrials.gov (NCT07629401). This describes a planned, ongoing, or completed study — it is NOT peer-reviewed results. Status: available. Study type: expanded_access. Sponsor: Eli Lilly and Company. Interventions: Retatrutide. Summary: Provide pre-approval single patient expanded access of retatrutide for patients. Eligibility: Inclusion Criteria: \- Exclusion Criteria: \-

View on ClinicalTrials.gov ↗

This is a registered clinical-trial record from ClinicalTrials.gov — a description of a planned, ongoing, or completed study, not peer-reviewed results. Listing on ClinicalTrials.gov does not mean the study has been evaluated by the U.S. Federal Government, nor does it imply endorsement or that the intervention is safe or effective.

Educational summary of published research — not medical advice. License: public-domain. Full text is shown only where licensing permits.